SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Strides Arcolab spurts on reporting stellar Q1 numbers

27 Apr 2012 Evaluate

Strides Arcolab is currently trading at Rs 659.00, up by 13.70 points or 2.12% from its previous closing of Rs 645.30 on the BSE.

The scrip opened at Rs 650.00 and has touched a high and low of Rs 669.00 and Rs 645.50 respectively. So far 10365 shares were traded on the counter.

The BSE group 'A' stock of face value Rs 10 has touched a 52 week high of Rs 681.00 on 20-Apr-2012 and a 52 week low of Rs 276.25 on 22-Aug-2011.

Last one week high and low of the scrip stood at Rs 677.75 and Rs 630.00 respectively. The current market cap of the company is Rs 3866.04 crore.

The promoters holding in the company stood at 28.35% while Institutions and Non-Institutions held 55.55% and 16.11% respectively.

Drug firm Strides Arcolab has reported a 15 fold jump in its consolidated net profit to Rs 642.07 crore for the first quarter ended March 31, 2012, primarily on the back of its entire stake sale in Australian arm Ascent Pharmahealth. The company had posted a net profit of Rs 40.71 crore in the same period last year.

The company’s net sales, on consolidated basis, stood at Rs 539.60 crore for the first quarter ended March 31, 2012, as against Rs 497.31 crore in the same period previous year.

On a standalone basis, the company posted a net loss of Rs 28.16 crore for the first quarter. It had posted a net profit of Rs 12.74 crore in the same period last year.

Strides Arcolab is a global pharmaceuticals headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceuticals products with an emphasis on sterile injectables.

Strides Pharma Scien Share Price

1000.70 6.80 (0.68%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×